{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:02:51Z","timestamp":1792785771173,"version":"4.5.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,26]],"date-time":"2020-03-26T00:00:00Z","timestamp":1585180800000},"content-version":"vor","delay-in-days":146,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Bayer AG and Loxo Oncology, Inc."},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1093\/annonc\/mdz282","type":"journal-article","created":{"date-parts":[[2019,8,22]],"date-time":"2019-08-22T15:30:50Z","timestamp":1566487850000},"page":"viii23-viii30","source":"Crossref","is-referenced-by-count":268,"special_numbering":"S8","title":["TRK inhibitors in TRK fusion-positive cancers"],"prefix":"10.1016","volume":"30","author":[{"given":"A.","family":"Drilon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1093\/annonc\/mdz282_bb0010","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.cell.2016.12.015","article-title":"Implementing genome-driven oncology","volume":"168","author":"Hyman","year":"2017","journal-title":"Cell"},{"issue":"6","key":"10.1093\/annonc\/mdz282_bb0015","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nm.4333","article-title":"Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients","volume":"23","author":"Zehir","year":"2017","journal-title":"Nat Med"},{"issue":"9","key":"10.1093\/annonc\/mdz282_bb0020","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1200\/JCO.2014.59.8433","article-title":"Basket trials and the evolution of clinical trial design in an era of genomic medicine","volume":"33","author":"Redig","year":"2015","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1093\/annonc\/mdz282_bb0025","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1093\/annonc\/mdz282_bb0030","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1093\/annonc\/mdz282_bb0035","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1158\/1535-7163.MCT-15-0758","article-title":"Entrectinib, a pan-TRK, ROS1, and ALK inhibitor with activity in multiple molecularly defined cancer indications","volume":"15","author":"Ardini","year":"2016","journal-title":"Mol Cancer Ther"},{"issue":"11","key":"10.1093\/annonc\/mdz282_bb0040","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1038\/nm.3352","article-title":"Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer","volume":"19","author":"Vaishnavi","year":"2013","journal-title":"Nat Med"},{"issue":"4","key":"10.1093\/annonc\/mdz282_bb0045","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1158\/2159-8290.CD-16-1237","article-title":"Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1)","volume":"7","author":"Drilon","year":"2017","journal-title":"Cancer Discov"},{"issue":"7","key":"10.1093\/annonc\/mdz282_bb0050","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1021\/acs.jmedchem.6b00064","article-title":"Discovery of entrectinib: a new 3-aminoindazole as a potent anaplastic lymphoma kinase (ALK), c-ros oncogene 1 kinase (ROS1), and pan-tropomyosin receptor kinases (Pan-TRKs) inhibitor","volume":"59","author":"Menichincheri","year":"2016","journal-title":"J Med Chem"},{"issue":"5","key":"10.1093\/annonc\/mdz282_bb0055","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1093\/annonc\/mdw042","article-title":"What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)","volume":"27","author":"Drilon","year":"2016","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1093\/annonc\/mdz282_bb0060","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1158\/2159-8290.CD-15-0443","article-title":"An oncogenic NTRK fusion in a patient with soft-tissue sarcoma with response to the tropomyosin-related kinase inhibitor LOXO-101","volume":"5","author":"Doebele","year":"2015","journal-title":"Cancer Discov"},{"issue":"12","key":"10.1093\/annonc\/mdz282_bb0065","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41571-018-0113-0","article-title":"NTRK fusion-positive cancers and TRK inhibitor therapy","volume":"15","author":"Cocco","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"10.1093\/annonc\/mdz282_bb0070","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1158\/1535-7163.MCT-16-0909","article-title":"Mechanisms of resistance to NTRK inhibitors and therapeutic strategies in NTRK1-rearranged cancers","volume":"16","author":"Fuse","year":"2017","journal-title":"Mol Cancer Ther"},{"issue":"Suppl 15","key":"10.1093\/annonc\/mdz282_bb0075","doi-asserted-by":"crossref","first-page":"10009","DOI":"10.1200\/JCO.2019.37.15_suppl.10009","article-title":"Phase 1\/1B trial to assess the activity of entrectinib in children and adolescents with recurrent or refractory solid tumors including central nervous system (CNS) tumors","volume":"37","author":"Robinson","year":"2019","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1093\/annonc\/mdz282_bb0080","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S1470-2045(18)30119-0","article-title":"Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1\/2 study","volume":"19","author":"Laetsch","year":"2018","journal-title":"Lancet Oncol"},{"issue":"Suppl 8","key":"10.1093\/annonc\/mdz282_bb0085","doi-asserted-by":"crossref","first-page":"viii133","DOI":"10.1093\/annonc\/mdy279.397","article-title":"Larotrectinib efficacy and safety in TRK fusion cancer: an expanded clinical dataset showing consistency in an age and tumor agnostic approach","volume":"29","author":"Lassen","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdz282_bb0090","first-page":"ix173","article-title":"Efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: pooled analysis of STARTRK-2, STARTRK-1, and ALKA-372-001","volume":"29","author":"Demetri","year":"2018","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1093\/annonc\/mdz282_bb0095","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1097\/01.JTO.0000473485.38553.f0","article-title":"Durable clinical response to entrectinib in NTRK1-rearranged non-small cell lung cancer","volume":"10","author":"Farago","year":"2015","journal-title":"J Thorac Oncol"},{"issue":"6","key":"10.1093\/annonc\/mdz282_bb0100","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s41416-018-0251-2","article-title":"Brief report: potent clinical and radiological response to larotrectinib in TRK fusion-driven high-grade glioma","volume":"119","author":"Ziegler","year":"2018","journal-title":"Br J Cancer"},{"issue":"Suppl 15","key":"10.1093\/annonc\/mdz282_bb0105","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1200\/JCO.2019.37.15_suppl.2006","article-title":"Activity of larotrectinib in TRK fusion cancer patients with brain metastases or primary central nervous system tumors","volume":"37","author":"Drilon","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdz282_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.19.00009","article-title":"Larotrectinib demonstrates CNS efficacy in TRK fusion-positive solid tumors","volume":"3","author":"Rosen","year":"2019","journal-title":"JCO Precis Oncol"},{"issue":"25","key":"10.1093\/annonc\/mdz282_bb0115","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1215530","article-title":"Acquired resistance to crizotinib from a mutation in CD74-ROS1","volume":"368","author":"Awad","year":"2013","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1093\/annonc\/mdz282_bb0120","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1158\/2159-8290.CD-16-0596","article-title":"Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer","volume":"6","author":"Gainor","year":"2016","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1093\/annonc\/mdz282_bb0125","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1158\/2159-8290.CD-15-0940","article-title":"Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer","volume":"6","author":"Russo","year":"2016","journal-title":"Cancer Discov"},{"issue":"9","key":"10.1093\/annonc\/mdz282_bb0130","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1158\/2159-8290.CD-17-0507","article-title":"A next-generation TRK kinase inhibitor overcomes acquired resistance to prior TRK kinase inhibition in patients with TRK fusion-positive solid tumors","volume":"7","author":"Drilon","year":"2017","journal-title":"Cancer Discov"},{"issue":"12","key":"10.1093\/annonc\/mdz282_bb0135","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/nrclinonc.2017.127","article-title":"Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance","volume":"14","author":"Schram","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1093\/annonc\/mdz282_bb0140","author":"Cocco"},{"issue":"10","key":"10.1093\/annonc\/mdz282_bb0145","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1158\/2159-8290.CD-18-0484","article-title":"Repotrectinib (TPX-0005) is a next-generation ROS1\/TRK\/ALK inhibitor that potently inhibits ROS1\/TRK\/ALK solvent- front mutations","volume":"8","author":"Drilon","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1093\/annonc\/mdz282_bb0150","series-title":"Presented at AACR Annual Meeting 2019, March 29\u2013April 3, Atlanta, GA","article-title":"Repotrectinib, a next generation TRK inhibitor, overcomes TRK resistance mutations including solvent front, gatekeeper and compound mutations","author":"Drilon","year":"2019"},{"key":"10.1093\/annonc\/mdz282_bb0155","series-title":"Phase I and expanded access experience of LOXO-195 (BAY 2731954), a selective next-generation TRK inhibitor (TRKi). In Proceedings of the 110th Annual Meeting of the American Association for Cancer Research; 2019 March 29\u20133 April 2019","author":"Hyman","year":"2019"},{"issue":"21","key":"10.1093\/annonc\/mdz282_bb0160","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1056\/NEJMoa1406766","article-title":"Crizotinib in ROS1-rearranged non-small-cell lung cancer","volume":"371","author":"Shaw","year":"2014","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1093\/annonc\/mdz282_bb0165","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1093\/annonc\/mdz282_bb0170","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/0092-8674(94)90048-5","article-title":"Snider WD. Functions of the neurotrophins during nervous system development: what the knockouts are teaching us","volume":"77","year":"1994","journal-title":"Cell"},{"issue":"6468","key":"10.1093\/annonc\/mdz282_bb0175","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/368249a0","article-title":"Disruption of the neurotrophin-3 receptor gene trkC eliminates la muscle afferents and results in abnormal movements","volume":"368","author":"Klein","year":"1994","journal-title":"Nature"},{"issue":"1","key":"10.1093\/annonc\/mdz282_bb0180","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0092-8674(05)80088-1","article-title":"Targeted disruption of the trkB neurotrophin receptor gene results in nervous system lesions and neonatal death","volume":"75","author":"Klein","year":"1993","journal-title":"Cell"},{"issue":"2","key":"10.1093\/annonc\/mdz282_bb0185","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/cne.20386","article-title":"Phenotype of cerebellar glutamatergic neurons is altered in stargazer mutant mice lacking brain-derived neurotrophic factor mRNA expression","volume":"481","author":"Richardson","year":"2005","journal-title":"J Comp Neurol"},{"key":"10.1093\/annonc\/mdz282_bb0190","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.2147\/TCRM.S147381","article-title":"Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors","volume":"14","author":"Liu","year":"2018","journal-title":"Ther Clin Risk Manag"},{"issue":"6468","key":"10.1093\/annonc\/mdz282_bb0195","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/368246a0","article-title":"Severe sensory and sympathetic neuropathies in mice carrying a disrupted Trk\/NGF receptor gene","volume":"368","author":"Smeyne","year":"1994","journal-title":"Nature"},{"issue":"4","key":"10.1093\/annonc\/mdz282_bb0200","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/ng0896-485","article-title":"Mutations in the TRKA\/NGF receptor gene in patients with congenital insensitivity to pain with anhidrosis","volume":"13","author":"Indo","year":"1996","journal-title":"Nat Genet"},{"issue":"11","key":"10.1093\/annonc\/mdz282_bb0210","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/nn1336","article-title":"A de novo mutation affecting human TrkB associated with severe obesity and developmental delay","volume":"7","author":"Yeo","year":"2004","journal-title":"Nat Neurosci"},{"issue":"7","key":"10.1093\/annonc\/mdz282_bb0215","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/nn1073","article-title":"Brain-derived neurotrophic factor regulates energy balance downstream of melanocortin-4 receptor","volume":"6","author":"Xu","year":"2003","journal-title":"Nat Neurosci"},{"key":"10.1093\/annonc\/mdz282_bb0220","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.10010","article-title":"Larotrectinib efficacy and safety in pediatric TRK fusion cancer patients","volume":"37","author":"van Tilburg","year":"2019","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdz282_bb0225","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1254\/jphs.91.267","article-title":"Brain-derived neurotrophic factor\/TrkB signaling in memory processes","volume":"91","author":"Yamada","year":"2003","journal-title":"J Pharmacol Sci"},{"issue":"1","key":"10.1093\/annonc\/mdz282_bb0230","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13075-016-0996-z","article-title":"Selective inhibition of tropomyosin-receptor-kinase A (TrkA) reduces pain and joint damage in two rat models of inflammatory arthritis","volume":"18","author":"Ashraf","year":"2016","journal-title":"Arthritis Res Ther"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419551146?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419551146?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/30\/Supplement_8\/viii23\/30959860\/mdz282.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/30\/Supplement_8\/viii23\/30959860\/mdz282.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T08:03:55Z","timestamp":1721635435000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419551146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":44,"alternative-id":["S0923753419551146"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdz282","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]}}}